for the AG221-C-001 Study Investigators IMPORTANCE Enasidenib mesylate, a mutant isocitrate dehydrogenase 2 (IDH2) protein inhibitor that promotes differentiation of leukemic myeloblasts, was recently approved by the US Food and Drug Administration for use in relapsed/refractory (R/R) mutant IDH2 acute myeloid leukemia (AML). During the first study of enasidenib in humans, a minority of patients with advanced myeloid neoplasms experienced unexpected signs/symptoms of a differentiation syndrome (DS), a potentially lethal entity.
G enetic and epigenetic alterations that block cellular differentiation underlie the development of myeloid neoplasms. 1 Agents that induce resumption of differentiation may be clinically beneficial; however, drug-induced differentiation of leukemic cells can be accompanied by a potentially serious condition, differentiation syndrome (DS), as seen during treatment of acute promyelocytic leukemia. [2] [3] [4] [5] Proliferation of differentiated leukemic cells can alter cytokine balance, leading to tissue damage and inflammation. 4 Signs and symptoms of DS include unexplained fever, weight gain, respiratory symptoms, and pleural or pericardial effusions. 4 Enasidenib mesylate (AG-221; IDHIFA; Celgene Corporation) is a first-in-class, oral inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2) proteins. Enasidenib was approved by the US Food and Drug Administration (FDA) in August 2017 for treatment of adult patients with mutant IDH2 (OMIM 147650) (mIDH2) relapsed/refractory acute myeloid leukemia (R/R AML). Mutant IDH2 proteins neomorphically catalyze the oncometabolite, (R)-2-hydroxyglutarate ([R]-2HG).
6 High (R)-2HG
concentrations promote hypermethylation, altered gene expression, and blocked differentiation of hematopoietic cells.
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Enasidenib suppresses 2HG and induces differentiation of mIDH2 leukemic cells, producing fully functioning neutrophils that retain the IDH2 mutation. 8, 9 Patients who respond to treatment with enasidenib exhibit evidence of hematopoietic recovery, typically without intervening bone marrow aplasia. 3, 8 In the first human, phase 1/2 study of enasidenib in patients with mIDH2 malignant hematologic neoplasms, investigators reported adverse events reminiscent of those seen in DS. Similar events have been reported for ivosidenib (AG-120), a mutant IDH1 protein inhibitor. 10 These signs and symptoms of mutant-IDH inhibitor-associated DS (termed IDH differentiation syndrome [IDH-DS]) 11 are nonspecific and can resemble other clinical conditions common in AML. To characterize IDH-DS and establish practicable diagnostic and therapeutic recommendations, an independent differentiation syndrome review committee (DSRC) retrospectively evaluated potential cases of IDH-DS among patients with R/R AML enrolled in the aforementioned study.
Methods
This was a multicenter, open-label, pivotal phase 1/2 study. Study design, conduct, eligibility criteria, and clinical response and safety assessments in the phase 1 dose-escalation and expansion study portions are reported elsewhere. 3 Phase 2 enrollment was limited to adult patients with R/R AML, all of whom received 100 mg of enasidenib once daily. This study was conducted in accordance with the Declaration of Helsinki.
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All patients provided written informed consent. The institutional review boards that approved the study can be found in the eAppendix in the Supplement. The DSRC independently reviewed cases of investigatorreported DS and those with adverse events suggestive of IDH-DS (eTable 1 in the Supplement). Isocitrate dehydrogenase differentiation syndrome was considered when characteristic signs and symptoms occurred in the absence of significant secondary causes, with concurrent evidence of cellular differentiation and proliferation in the blood or bone marrow, and with subsequent clinical response to corticosteroid therapy. 
Results
Two hundred eighty-one patients with R/R AML participated between August 27, 2013, and data cutoff (October 14, 2016). Findings In a phase 1/2 clinical trial of 281 patients with relapsed/ refractory acute myeloid leukemia treated with enasidenib, possible or probable isocitrate dehydrogenase differentiation syndrome was identified in 33 patients and had recognizable signs and symptoms, including dyspnea, unexplained fever, pulmonary infiltrates, and hypoxia. These signs and symptoms could occur months after initiation of enasidenib treatment and could mimic symptoms seen during treatment and progression of myeloid neoplasms; prompt intervention with systemic corticosteroid therapy was an effective management approach.
Meaning As use of mutant isocitrate dehydrogenase inhibitors increases, awareness of the potential for isocitrate dehydrogenase differentiation syndrome is imperative so that patients can be promptly and effectively treated.
The DSRC reviewed 72 suspected cases of IDH-DS and, of them, identified 33 patients (11.7% of all patients with R/R AML) as having experienced possible or probable IDH-DS. The median age of patients with possible or probable IDH-DS was 70 years (range, 38-80 years). Twenty of the 33 (60.6%) were male. Twenty-five patients had 1 IDH-DS episode, 6 had 2 episodes, and 2 experienced 3 episodes. Reasons for rejecting an IDH-DS diagnosis included alternative causes for symptoms, lack of clinical evidence of cellular differentiation, lack of response to corticosteroid therapy, and clear evidence of disease progression as a more likely explanation for the constellation of clinical signs and/or symptoms. Baseline characteristics were generally comparable between patients who experienced IDH-DS and those who did not (eTable 2 in the Supplement). Patients with IDH-DS were significantly less likely to have had less than 20% bone marrow blasts (6% vs 22%, P = .04) and more likely to have undergone a lower median number of previous antileukemic regimens (median, 1.0 [range, 1-4] vs 2.0 [range, 1-14], P = .05). Higher peripheral blast counts (median 31% [range, 0%-88%] vs 13% [range, 0%-98%], P = .05) and greater proportion of those with lactate dehydrogenase levels above 1 × upper limit of normal (51% vs 36%, P = .09) were noted for patients with IDH-DS, but these variables did not reach statistical significance. In multivariate analysis, only a lesser median number of previous antileukemic therapies was significantly associated with IDH-DS (odds ratio, 0.66; 95% CI, 0.44-1.00; P = .05).
Median time from beginning of enasidenib treatment to IDH-DS onset was 30 days (range, 7-129 days); onset at day 129 occurred for 1 patient after a treatment interruption of approximately 1 month. The most frequent clinical manifestations of IDH-DS were dyspnea, culture-negative fever, pulmonary infiltrates, and hypoxia ( Table 1) . Ten patients required intensive care unit admission for related symptoms. Leukocytosis occurred concurrently in 13 patients. No death was attributed to IDH-DS. Clinical and laboratory profiles for 2 illustrative cases in patients who experienced IDH-DS are described in eFigures 1 and 2 in the Supplement. Dosages greater and less than 100 mg/d were evaluated in small patient cohorts during dose escalation. Events related to IDH-DS occurred in none of 19 patients with R/R AML receiving enasidenib dosages less than 100 mg/d, 26 of 214 patients (12.1%) receiving 100 mg/d, and 7 of 48 patients (14.6%) receiving greater than 100 mg/d. Frequency of IDH-DS was not statistically different among these groups.
IDH-DS Management
Twenty-eight of the 33 patients with IDH-DS (84.8%) received symptomatic treatment with corticosteroids. For 20 patients with available data, median duration of corticosteroid therapy for IDH-DS was 12 days (range, 4-43 days). Eleven of 13 patients with concomitant leukocytosis received hydroxyurea (median, 15 days [range, 4-71 days]). The enasidenib regimen was interrupted for 15 patients (45.5%) until IDH-DS symptoms improved. Two patients (6.1%) had dosage reduced, but none discontinued enasidenib therapy permanently because of IDH-DS.
Isocitrate dehydrogenase differentiation syndrome management guidelines have been incorporated into an amended protocol. At first suspicion of IDH-DS, dexamethasone, 10 mg twice daily, is recommended until signs and symptoms are significantly improved (Figure) .
Efficacy
Overall response rate for patients with IDH-DS was 45.5% (15 of 33 patients) and for patients without IDH-DS, 37.5% (93 of 248) ( Table 2) . Complete remission or complete remission with incomplete platelet or neutrophil count recovery was experienced by 36.4% of patients (12 of 33) in the IDH-DS group and 26.2% (65 of 248) in the non-IDH-DS group (P = .22). Disease remained stable in approximately half of the patients in each group.
Discussion
Isocitrate dehydrogenase differentiation syndrome is a newly defined clinical entity in patients with mIDH2 AML receiving enasidenib, likely owing to the drug's mechanism of action, promoting differentiation of myeloblasts into mature cells. Our results showed that IDH-DS was significantly associated with fewer previous anticancer therapies and nonsignificantly associated with higher baseline peripheral blast counts (P = .05) and lactate dehydrogenase levels (P = .09), both laboratory markers suggestive of cellular turnover. Why fewer preceding therapies might increase risk is unclear. This IDH-DS study population is small; further study is needed to determine whether reliable biomarkers of the potential to develop IDH-DS exist.
The rate of IDH-DS with enasidenib (11.7%) was lower than DS rates reported with all-trans retinoic acid or arsenic trioxide in acute promyelocytic leukemia .
5,15 Unlike all-trans retinoic acid-or arsenic trioxide-induced DS, which have a typical onset of approximately 7 to 12 days from treatment initiation), 4 IDH-DS onset can occur from 7 days to 5 months after initiation of enasidenib treatment. In addition, IDH-DS can occur after enasidenib therapy interruption or dose escalation. Onset appears to correspond to enasidenib-induced myeloid cell differentiation and maturation, similar to the "neutrophil surge" associated with DS in patients treated with FLT3 (FMS-like tyrosine kinase 3) inhibitors, such as quizartinib. 2 Although potentially life-threatening, IDH-DS can be effectively managed. When alternative secondary causes for characteristic symptoms are excluded or do not respond to treatment, or if symptoms worsen within 48 hours of initiating treatment for a different suspected cause, the event should be managed as potential IDH-DS (Figure) . For concomitant leukocytosis, cytoreduction per local standard practice is recommended.
Approximately half of patients with IDH-DS received enasidenib therapy without interruption. If associated with severe pulmonary symptoms and/or renal dysfunction lasting more than 48 hours after corticosteroid treatment initiation, enasidenib therapy should be withheld until symptoms improve. Symptoms may not resolve immediately. Given the prolonged half-life of enasidenib (approximately 137 hours), 16 drug treatment interruption is not an alternative to corticosteroid use.
Limitations
The studied population was relatively small, and larger studies are needed. In addition, because IDH-DS was not initially anticipated, the protocol did not define proactive monitoring for it; however, IDH-DS monitoring is now part of clinical protocols for enasidenib studies.
Conclusions
As use of mutant-IDH inhibitors increases, these recommendations are increasingly germane to care of patients with mutant-IDH hematologic neoplasms.
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The identification of IDH mutations in the AML genome dates back to 2009. 1 Massively parallel DNA sequencing performed on a de novo AML genome alongside a matched skin genome showed a mutation in IDH1 (OMIM 147700), and 15 of 187 additional AML genomes tested were found to harbor deleterious IDH1 mutations. 1 The functional significance of IDH1 and IDH2 (OMIM 147650) mutations was demonstrated in 2010 with the discovery that neomorphic enzyme activity arising from the mutation leads to the production of 2-hydroxyglutarate. 2 This metabolite leads to epigenetic alterations, including DNA and histone methylation, ultimately resulting in a differentiation block in myeloid cells. 2 In contrast, wild-type IDH catalyzes the conversion of isocitrate to α-ketoglutarate and permits normal cellular metabolism. In 2014, it was shown that preleukemic 
